Germline ERBB2/HER2 Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms

被引:4
|
作者
Braunstein, Evan M. [1 ]
Chen, Hang [1 ]
Juarez, Felicia [1 ]
Yang, Fanghan [1 ]
Tao, Lindsay [1 ]
Makhlin, Igor [2 ]
Williams, Donna M. [1 ]
Chaturvedi, Shruti [1 ]
Pallavajjala, Aparna [3 ]
Karantanos, Theodoros [4 ]
Martin, Renan [5 ]
Wohler, Elizabeth [5 ]
Sobreira, Nara [5 ]
Gocke, Christopher D. [3 ,4 ]
Moliterno, Alison R. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Div Haematol, Baltimore, MD 21205 USA
[2] Univ Penn, Div Hematol Oncol, Dept Med, Philadelphia, PA 19104 USA
[3] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[4] Johns Hopkins Univ, Sch Med, Dept Med Oncol, Baltimore, MD 21205 USA
[5] Johns Hopkins Univ, Sch Med, McKusick Nathans Dept Genet Med, Baltimore, MD 21205 USA
关键词
familial cancer; myeloproliferative neoplasms; germline predisposition; BREAST-CANCER; INHERITED SUSCEPTIBILITY; JAK2; HAPLOTYPE; MUTATIONS; COMMON; PREDISPOSITION; POLYMORPHISM; GENE;
D O I
10.3390/cancers13133246
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Familial clustering of myeloproliferative neoplasms (MPN) is well known, with a 5- to 7-fold increased risk of MPN among first-degree relatives of MPN patients. However, the genetic susceptibility of this disease remains poorly understood. Exome sequencing of a familial MPN pedigree followed by a case-control analysis identified germline variants in the HER2/ERBB2 gene that associate with the MPN phenotype. ERBB2/HER2 is a novel susceptibility locus which contributes to cancer risk in combination with additional risk alleles. Familial cases of myeloproliferative neoplasms (MPN) are relatively common, yet few inherited risk factors have been identified. Exome sequencing of a kindred with a familial cancer syndrome characterized by both MPN and melanoma produced a germline variant in the ERBB2/HER2 gene that co-segregates with disease. To further investigate whether germline ERBB2 variants contribute to MPN predisposition, the frequency of ERBB2 variants was analyzed in 1604 cases that underwent evaluation for hematologic malignancy, including 236 cases of MPN. MPN cases had a higher frequency of rare germline ERBB2 coding variants compared to non-MPN hematologic malignancies (8.9% vs. 4.1%, OR 2.4, 95% CI: 1.4 to 4.0, p = 0.0028) as well as cases without a blood cancer diagnosis that served as an internal control (8.9% vs. 2.7%, OR 3.5, 95% CI: 1.4 to 8.3, p = 0.0053). This finding was validated via comparison to an independent control cohort of 1587 cases without selection for hematologic malignancy (8.9% in MPN cases vs. 5.2% in controls, p = 0.040). The most frequent variant identified, ERBB2 c.1960A > G; p.I654V, was present in MPN cases at more than twice its expected frequency. These data indicate that rare germline coding variants in ERBB2 are associated with an increased risk for development of MPN. The ERBB2 gene is a novel susceptibility locus which likely contributes to cancer risk in combination with additional risk alleles.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] HER2 therapy - HER2 (ERBB2): functional diversity from structurally conserved building blocks
    Landgraf, Ralf
    BREAST CANCER RESEARCH, 2007, 9 (01)
  • [22] Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
    Reid, Alison
    Vidal, Laura
    Shaw, Heather
    de Bono, Johann
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (03) : 481 - 489
  • [23] ErbB2 (HER2)-positives MammakarzinomResistenzmechanismenErbB2 (HER2) positive breast cancer Mechanisms of resistance
    K. Kast
    W. Distler
    Der Gynäkologe, 2010, 43 (7): : 574 - 578
  • [24] HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks
    Ralf Landgraf
    Breast Cancer Research, 9
  • [25] ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer
    David F. Stern
    Journal of Mammary Gland Biology and Neoplasia, 2008, 13
  • [26] Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
    Harari, D
    Yarden, Y
    ONCOGENE, 2000, 19 (53) : 6102 - 6114
  • [27] ERBB2 (HER2) Gene Amplification and Protein Overexpression in Ampullary Carcinoma
    Hechtman, Jaclyn
    Arcila, Maria
    Vakiani, Efsevia
    Shia, Jinru
    Klimstra, David
    MODERN PATHOLOGY, 2015, 28 : 165A - 165A
  • [28] HER2/ERBB2 Testing in Breast Carcinoma by Next Generation Sequencing
    Wong, Adele
    Bhan, Atul
    Lennerz, Jochen K.
    Brachtel, Elena
    MODERN PATHOLOGY, 2017, 30 : 522A - 522A
  • [29] Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
    Daniel Harari
    Yosef Yarden
    Oncogene, 2000, 19 : 6102 - 6114
  • [30] ErbB2/HER2/Neu resembles an autoinhibited invertebrate EGF receptor
    Alvarado, Diego
    Klein, Daryl E.
    Lemmon, Mark A.
    FASEB JOURNAL, 2009, 23